Gemcitabine
1 g/m
2
days 1 & 8 +
Sunitinib
37.5 mg/day, days 1‐14, every 21 days.
39 sarcomatoid pts (+ 33 poor‐risk pts).
ORR
: 26%;
TTP
: 5 mo; OS 10 mo.
Pts with > 10% sarcomatoid component had a higher clinical benefit rate than
those with < 10% sarcomatoid.
Grade 3‐4 toxicity: Neutropenia (20%), anemia (10%), fatigue (9%).
Michaelson MD, et al. Cancer 2015; 121:3435‐43
